The results of a new study using the drug Tolterodine ER were presented at the American Urogynecologic Society 29th Annual Scientific Meeting (AUGS) last week.

Tolterodine ER reduces overactive bladder symptoms and health-related quality of life (HRQL) significantly.

The study enrolled 202 women for treatment with Tolterodine ER or placebo for 12 weeks. After the 12 weeks women who had taken Tolterodine Er showed significant reduction in overactive bladder symptoms.

The second phase of study was a 12 week open label phase and 161 women who remained in the study continued to be treated with Tolterodine ER, results at the end of 12 week period were maintained or became significantly improved.

Doctors noted that long-term pharmacotherapy may be important to optimise treatment outcomes.